CG Oncology Inc
CGONHealthcare|Biotechnology|USA
$75.24
+1.89 (+2.58%)
Tangible Book
$12.28
About
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Stock Price
+177.5%(1Y)
Pipeline Summary
9 total trials1
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
Withdrawn: 1Recruiting: 1AVAILABLE: 1Terminated: 1Active: 2Completed: 3
Active Trials (3)
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
NCT06567743High-Risk Non-Muscle-Invasive Bladder Cancer
Phase 2Recruiting
Enrollment: 325 participants
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT04452591Non Muscle Invasive Bladder Cancer
Phase 3Active
Enrollment: 190 participants
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235Non Muscle Invasive Bladder Cancer
Phase 3Active
Enrollment: 367 participants
BioScore
5.6/10
Watchlist
Ownership
Recent Insider Trades
Liu Brian Guan-ChyunBUY
2026-06-25371,085 shares @ $66.87
POST LEONARD ESELL
2026-06-245,000 shares @ $70
POST LEONARD ESELL
2026-06-225,000 shares @ $65
Mulay JamesSELL
2026-06-151,964 shares @ $60.12
POST LEONARD ESELL
2026-06-041,000 shares @ $54.5
Recent News
2026-06-25 13:25:30
Data last updated: Jul 12, 2026, 07:40 PM